10,466 Shares in Solventum Co. (NYSE:SOLV) Bought by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. acquired a new position in Solventum Co. (NYSE:SOLV - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,466 shares of the company's stock, valued at approximately $730,000.

A number of other hedge funds have also made changes to their positions in SOLV. Price T Rowe Associates Inc. MD acquired a new position in Solventum during the 1st quarter worth approximately $5,889,000. EverSource Wealth Advisors LLC acquired a new stake in Solventum during the 1st quarter valued at $30,000. GAMMA Investing LLC purchased a new stake in Solventum during the 2nd quarter worth $74,000. Massmutual Trust Co. FSB ADV acquired a new position in Solventum in the 2nd quarter worth $34,000. Finally, DNB Asset Management AS purchased a new position in Solventum in the 2nd quarter valued at about $1,227,000.

Solventum Stock Up 1.0 %

Shares of NYSE:SOLV traded up $0.69 on Monday, reaching $72.20. 514,469 shares of the company's stock were exchanged, compared to its average volume of 1,682,155. The business's 50-day moving average is $70.55 and its two-hundred day moving average is $62.58. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on SOLV shares. BTIG Research assumed coverage on Solventum in a research report on Thursday, September 5th. They set a "neutral" rating on the stock. Wolfe Research initiated coverage on Solventum in a report on Thursday, September 26th. They set a "peer perform" rating on the stock. The Goldman Sachs Group increased their target price on Solventum from $48.00 to $54.00 and gave the company a "sell" rating in a research note on Monday, August 12th. Wells Fargo & Company dropped their price target on shares of Solventum from $69.00 to $64.00 and set an "equal weight" rating for the company in a research note on Friday, August 9th. Finally, Piper Sandler increased their price objective on shares of Solventum from $71.00 to $75.00 and gave the company a "neutral" rating in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Solventum presently has a consensus rating of "Hold" and an average price target of $68.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.